Cepheid Reports Q1 Revenue of $6B, Plans to Acquire Masimo
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9 hours ago
0mins
Should l Buy DHR?
Reports Q1 revenue $6B, consensus $6B. Rainer Blair, President and CEO, stated, "Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth. On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid. We were also pleased to announce our intention to acquire Masimo Corporation, a leading provider of mission-critical pulse oximetry and patient monitoring solutions in acute care settings. We believe there are clear opportunities to enhance Masimo's performance through DBS and our global scale. Looking ahead, the strength of our balance sheet and free cash flow generation provides additional capacity for value-creating capital deployment."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 195.500
Low
240.00
Averages
266.18
High
310.00
Current: 195.500
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher Reports Q1 2026 Results with Strong EPS Growth and Acquisition Plans
- Significant Earnings Growth: Danaher reported net earnings of $1.029 billion for Q1 2026, a 7.8% increase year-over-year, indicating strong performance in bioprocessing and life sciences, despite a weaker-than-typical respiratory season, showcasing the company's recovery capability.
- EPS Improvement: The adjusted EPS grew nearly 10% to $2.06, exceeding market expectations, reflecting the company's successful execution in driving productivity and innovation, which bolsters investor confidence.
- Acquisition Announcement: Danaher announced its intention to acquire Masimo Corporation, a leader in acute care monitoring solutions, which is expected to enhance Masimo's performance through Danaher's global scale and business system, further expanding market share.
- Optimistic Future Outlook: The company anticipates core revenue growth of 3% to 6% for the full year 2026 and has raised its adjusted EPS guidance to a range of $8.35 to $8.55, demonstrating strong cash flow and capital deployment capacity, enhancing the potential for long-term shareholder value creation.
See More
Danaher Q1 2026 Earnings Call Insights
- Performance Highlights: Danaher reported $6 billion in sales for Q1 2026, with core revenue up 0.5% year-over-year; despite a 2.5% headwind from respiratory revenue, strong performance in bioprocessing and Life Sciences effectively offset this impact, demonstrating the company's resilience in the market.
- Profitability Improvement: Adjusted diluted net earnings per share reached $2.06, reflecting a 9.5% year-over-year increase, while free cash flow totaled $1.1 billion, achieving a conversion ratio of 105% from net income, indicating robust cash generation capabilities.
- Acquisition Strategy: Danaher is enhancing its portfolio through the acquisition of Masimo, which is expected to positively impact adjusted diluted net earnings per share in the first year post-acquisition and deliver high single-digit returns on invested capital by the fifth year, showcasing confidence in future growth.
- Market Outlook: Although the 2026 respiratory revenue outlook has been revised down to $1.6 billion to $1.7 billion, the company maintains its core revenue growth expectation of 3% to 6%, with management expressing optimism about market recovery, particularly in the bioprocessing sector in China, which is showing double-digit growth.
See More
Danaher Corp. Shows Strength Amid Biotech Recovery
- Biotech Funding Recovery: After four years of tightening, early 2026 data indicates that biopharma spending is stabilizing and beginning to recover, with contract research firms and suppliers reporting improved demand, suggesting loosening funding conditions and a resurgence in deal activity that could present new growth opportunities for the sector.
- Danaher's Financial Performance: In 2025, Danaher generated $24.6 billion in total revenue, growing approximately 3% year-over-year despite a weak biotech funding environment, demonstrating its resilience and sustained market demand within the industry.
- Strong Cash Flow: Danaher produced about $5.3 billion in free cash flow in 2025, compared to $3.6 billion in net income, achieving a cash flow conversion rate of 145%, indicating high operational efficiency and the ability to maintain profitability even during industry downturns.
- Future Growth Outlook: Management projects revenue growth of 3% to 6% for 2026, with expected earnings per share of $8.35 to $8.50; if capital flows into biotech increase significantly, revenue growth could be even higher, reflecting the company's potential benefits from the sector's recovery.
See More
Mixed Earnings Reports from Multiple Companies
- UnitedHealth Earnings Beat: UnitedHealth reported Q1 earnings of $7.23 per share and revenue of $11.72 billion, surpassing analyst expectations of $6.57 and $109.57 billion, while also raising its full-year earnings outlook, indicating strong market performance and growth potential.
- Amazon's Major Investment: Amazon has agreed to invest up to $25 billion in AI startup Anthropic, following an earlier $8 billion investment, with Anthropic committing to spend over $100 billion on Amazon Web Services over the next decade, highlighting Amazon's strategic positioning in AI infrastructure.
- GE Aerospace Strong Performance: GE Aerospace reported Q1 earnings of $1.86 per share and revenue of $11.61 billion, exceeding analyst expectations of $1.60 and $10.72 billion, showcasing the company's competitiveness and profitability in the aerospace market.
- D.R. Horton Mixed Results: D.R. Horton reported Q2 earnings of $2.24 per share, beating the $2.15 forecast, but revenue of $7.56 billion fell short of the $7.60 billion expectation, reflecting the volatility and challenges in the real estate market.
See More
Danaher Corporation Reports Strong EPS Beat Despite Revenue Miss
- Earnings Beat: Danaher Corporation (DHR) reported a non-GAAP EPS of $2.06, exceeding market expectations by $0.12, indicating strong profitability despite challenges in revenue generation.
- Revenue Miss: The company’s revenue of $5.95 billion fell short of expectations by $50 million, suggesting potential headwinds in certain business segments amid the current economic climate, which could impact future performance.
- Long-Term Investment Appeal: Despite the revenue miss, Danaher remains an attractive option for long-term dividend growth investors due to its consistent profitability and commitment to dividend payments, reinforcing investor confidence.
- Market Dynamics: The addition of Ecolab and GE Vernova to the Mar Vista U.S. Quality Premier fund, along with the exit of Salesforce and SAP, highlights shifting market dynamics that could influence investor sentiment and strategic positioning in the healthcare sector.
See More
Danaher Raises Full-Year Earnings Outlook Amid Mixed Q1 Results
- Earnings Outlook Raised: Danaher has raised its non-GAAP diluted EPS outlook to a range of $8.35 to $8.55, with a midpoint of $8.45, surpassing the consensus estimate of $8.40, indicating strong confidence in future profitability.
- Revenue Miss: Despite a ~4% YoY revenue growth to $5.95 billion in Q1, the figure fell short of forecasts by $50 million, primarily due to a ~2% YoY contraction in the Diagnostics segment, which negatively impacted overall performance.
- Segment Growth: The Biotechnology and Life Sciences segments achieved ~12% and ~4% YoY growth, respectively, contributing $1.74 billion and $1.80 billion to revenue, both exceeding market expectations, highlighting the company's strong performance in these areas.
- Operational Efficiency Improvement: Danaher's non-GAAP EPS grew ~10% YoY to $2.06, beating Street forecasts by $0.12, while the adjusted operating margin improved by 60 basis points to 30.2%, reflecting enhancements in cost control and profitability.
See More
Danaher Reports Q1 2026 Results with Strong EPS Growth and Acquisition Plans
- Significant Earnings Growth: Danaher reported net earnings of $1.029 billion for Q1 2026, a 7.8% increase year-over-year, indicating strong performance in bioprocessing and life sciences, despite a weaker-than-typical respiratory season, showcasing the company's recovery capability.
- EPS Improvement: The adjusted EPS grew nearly 10% to $2.06, exceeding market expectations, reflecting the company's successful execution in driving productivity and innovation, which bolsters investor confidence.
- Acquisition Announcement: Danaher announced its intention to acquire Masimo Corporation, a leader in acute care monitoring solutions, which is expected to enhance Masimo's performance through Danaher's global scale and business system, further expanding market share.
- Optimistic Future Outlook: The company anticipates core revenue growth of 3% to 6% for the full year 2026 and has raised its adjusted EPS guidance to a range of $8.35 to $8.55, demonstrating strong cash flow and capital deployment capacity, enhancing the potential for long-term shareholder value creation.
See More
Danaher Q1 2026 Earnings Call Insights
- Performance Highlights: Danaher reported $6 billion in sales for Q1 2026, with core revenue up 0.5% year-over-year; despite a 2.5% headwind from respiratory revenue, strong performance in bioprocessing and Life Sciences effectively offset this impact, demonstrating the company's resilience in the market.
- Profitability Improvement: Adjusted diluted net earnings per share reached $2.06, reflecting a 9.5% year-over-year increase, while free cash flow totaled $1.1 billion, achieving a conversion ratio of 105% from net income, indicating robust cash generation capabilities.
- Acquisition Strategy: Danaher is enhancing its portfolio through the acquisition of Masimo, which is expected to positively impact adjusted diluted net earnings per share in the first year post-acquisition and deliver high single-digit returns on invested capital by the fifth year, showcasing confidence in future growth.
- Market Outlook: Although the 2026 respiratory revenue outlook has been revised down to $1.6 billion to $1.7 billion, the company maintains its core revenue growth expectation of 3% to 6%, with management expressing optimism about market recovery, particularly in the bioprocessing sector in China, which is showing double-digit growth.
See More
Danaher Corp. Shows Strength Amid Biotech Recovery
- Biotech Funding Recovery: After four years of tightening, early 2026 data indicates that biopharma spending is stabilizing and beginning to recover, with contract research firms and suppliers reporting improved demand, suggesting loosening funding conditions and a resurgence in deal activity that could present new growth opportunities for the sector.
- Danaher's Financial Performance: In 2025, Danaher generated $24.6 billion in total revenue, growing approximately 3% year-over-year despite a weak biotech funding environment, demonstrating its resilience and sustained market demand within the industry.
- Strong Cash Flow: Danaher produced about $5.3 billion in free cash flow in 2025, compared to $3.6 billion in net income, achieving a cash flow conversion rate of 145%, indicating high operational efficiency and the ability to maintain profitability even during industry downturns.
- Future Growth Outlook: Management projects revenue growth of 3% to 6% for 2026, with expected earnings per share of $8.35 to $8.50; if capital flows into biotech increase significantly, revenue growth could be even higher, reflecting the company's potential benefits from the sector's recovery.
See More
Mixed Earnings Reports from Multiple Companies
- UnitedHealth Earnings Beat: UnitedHealth reported Q1 earnings of $7.23 per share and revenue of $11.72 billion, surpassing analyst expectations of $6.57 and $109.57 billion, while also raising its full-year earnings outlook, indicating strong market performance and growth potential.
- Amazon's Major Investment: Amazon has agreed to invest up to $25 billion in AI startup Anthropic, following an earlier $8 billion investment, with Anthropic committing to spend over $100 billion on Amazon Web Services over the next decade, highlighting Amazon's strategic positioning in AI infrastructure.
- GE Aerospace Strong Performance: GE Aerospace reported Q1 earnings of $1.86 per share and revenue of $11.61 billion, exceeding analyst expectations of $1.60 and $10.72 billion, showcasing the company's competitiveness and profitability in the aerospace market.
- D.R. Horton Mixed Results: D.R. Horton reported Q2 earnings of $2.24 per share, beating the $2.15 forecast, but revenue of $7.56 billion fell short of the $7.60 billion expectation, reflecting the volatility and challenges in the real estate market.
See More
Danaher Corporation Reports Strong EPS Beat Despite Revenue Miss
- Earnings Beat: Danaher Corporation (DHR) reported a non-GAAP EPS of $2.06, exceeding market expectations by $0.12, indicating strong profitability despite challenges in revenue generation.
- Revenue Miss: The company’s revenue of $5.95 billion fell short of expectations by $50 million, suggesting potential headwinds in certain business segments amid the current economic climate, which could impact future performance.
- Long-Term Investment Appeal: Despite the revenue miss, Danaher remains an attractive option for long-term dividend growth investors due to its consistent profitability and commitment to dividend payments, reinforcing investor confidence.
- Market Dynamics: The addition of Ecolab and GE Vernova to the Mar Vista U.S. Quality Premier fund, along with the exit of Salesforce and SAP, highlights shifting market dynamics that could influence investor sentiment and strategic positioning in the healthcare sector.
See More
Danaher Raises Full-Year Earnings Outlook Amid Mixed Q1 Results
- Earnings Outlook Raised: Danaher has raised its non-GAAP diluted EPS outlook to a range of $8.35 to $8.55, with a midpoint of $8.45, surpassing the consensus estimate of $8.40, indicating strong confidence in future profitability.
- Revenue Miss: Despite a ~4% YoY revenue growth to $5.95 billion in Q1, the figure fell short of forecasts by $50 million, primarily due to a ~2% YoY contraction in the Diagnostics segment, which negatively impacted overall performance.
- Segment Growth: The Biotechnology and Life Sciences segments achieved ~12% and ~4% YoY growth, respectively, contributing $1.74 billion and $1.80 billion to revenue, both exceeding market expectations, highlighting the company's strong performance in these areas.
- Operational Efficiency Improvement: Danaher's non-GAAP EPS grew ~10% YoY to $2.06, beating Street forecasts by $0.12, while the adjusted operating margin improved by 60 basis points to 30.2%, reflecting enhancements in cost control and profitability.
See More
